2020
DOI: 10.1080/14712598.2021.1841164
|View full text |Cite
|
Sign up to set email alerts
|

Anti-IFNαR Mabs for the treatment of systemic lupus erythematosus

Abstract: Introduction: The type 1 interferon pathway is known to play a role in the immunopathology of Systemic Lupus Erythematosus (SLE). As a result, biologic agents targeting this pathway have been developed and are currently being investigated in clinical trials. Areas covered: We review the biologic agents which have been developed to antagonise type I interferons in SLE. We focus on anifrolumab, a type I interferon receptor antagonist, and consider the complexities of defining efficacy in SLE clinical trials. Exp… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
8
0
10

Year Published

2021
2021
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(18 citation statements)
references
References 62 publications
0
8
0
10
Order By: Relevance
“…This is the strategy behind anifrolumab, a fully human monoclonal antibody against the type I IFN receptor subunit 1 [171,172]. The drug is well-tolerated and was found to improve plasma cholesterol efflux capacity in a randomized placebo-controlled study of SLE patients [68,173].…”
Section: Novel Therapeuticsmentioning
confidence: 99%
“…This is the strategy behind anifrolumab, a fully human monoclonal antibody against the type I IFN receptor subunit 1 [171,172]. The drug is well-tolerated and was found to improve plasma cholesterol efflux capacity in a randomized placebo-controlled study of SLE patients [68,173].…”
Section: Novel Therapeuticsmentioning
confidence: 99%
“…11 Recent data from randomised controlled trials show that blocking the type I IFN receptor by anifrolumab decreases global disease activity in SLE. 12 Corresponding studies in pSS are lacking but a phase I open-label study in SSc has been conducted, and recent studies indicate that type I IFN signalling is important also in SSc. [13][14][15] Another similarity between the three diseases is the high prevalence of autoantibodies, for example, antibodies targeting cellular antigens referred to as ANA usually detected by immunofluorescence (IF) microscopy on HEp-2 cells and/or antigen-specific assays.…”
Section: How This Study Might Affect Research Practice or Policymentioning
confidence: 99%
“…В свою очередь НК и ИК, связываясь с TLR7 и TLR9, локализованными в эндосомах плазмоцитоидных дендритных клеток (ДК), индуцируют синтез ИФН типа I (а также ИФН типа III). Комплекс данных, полученных в процессе фундаментальных и клинических исследований, послужил основанием для разработки нового подхода к фармакотерапии СКВ, связанного с использованием мАТ, блокирующих активность рецепторов ИФН типа I [162][163][164]. В ряду этих препаратов особое место занимает анифролумаб (АФМ), представляющий собой человеческие мАТ к IgG1, блокирующие рецептор ИФН-α -IFNAR1 (Interferon Alpha and Beta Receptor Subunit 1) с высокой афинностью и специфичностью [91,165,166].…”
Section: проблемы системной красной волчанки в XXI векеunclassified